(E)-3-(2-benzyloxy-5-bromophenyl)prop-2-enoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(2-benzyloxy-5-bromophenyl)prop-2-enoic acid
• 英文别名: (E)-3-(5-bromo-2-benzyloxyphenyl)propenoic acid；(2E)-3-[2-(benzyloxy)-5-bromophenyl]prop-2-enoic acid；(E)-3-(5-bromo-2-phenylmethoxyphenyl)prop-2-enoic acid
• 化学式: C₁₆H₁₃BrO₃
• mdl: MFCD02257428
• 分子量: 333.181
• InChiKey: KTQCYOABVYGDNK-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.062
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES
  申请人：CRYSTAL PHARMA, S.A.U.

  公开号：US20150094485A1

  公开（公告）日：2015-04-02

  3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, can be produced by treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV′), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.

  一般式（I）的3,3-二苯基丙基胺，特别是费索特罗定（Fesoterodine），以及它们的对映体、溶剂合物和盐类，可以通过用手性醇处理一种具有式（II）的化合物来生产，以得到式（IV）和（IV'）的对映异构酯，然后可以进一步转化为具有式（I）的化合物，或其对映体、溶剂合物或盐类，其中R1为C1-C8烷基；R2和R3分别表示H或C1-C6烷基，或者一起形成一个由3到7个成员组成的环，与它们结合的氮原子。
• Carboxilic acid derivatives
  申请人：YAMAGUCHI Youichi

  公开号：US20080275116A1

  公开（公告）日：2008-11-06

  A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): wherein R 1 represents a C 6-10 aryl group; or a substituted C 6-10 aryl group, R 2 represents a C 6-10 aryl group; or a C 6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, nitro group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group, a phenyl group and carboxy group, X represents —CH 2 —, —CH 2 CH 2 —, —CH═CH— or —N(R 3 )—C(═O)—, Y represents carboxy group or a bioisostere of carboxy group, R 3 represents hydrogen atom, a C 1-4 alkyl group or a C 7-12 aralkyl group, m represents 0 or 1.

  以下通用公式（I）代表的化合物或其盐，或其水合物或溶剂合物，具有对纤溶酶原激活抑制剂-1（PAI-1）的抑制作用：其中R1代表C6-10芳基；或取代的C6-10芳基，R2代表C6-10芳基；或取代的C6-10芳基，取代基或取代基组成的组中选择的卤素原子，硝基基团，C1-6烷基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，苯基和羧基，X代表-CH2-，- -，-CH═CH-或-N（R3）-C（=O）-，Y代表羧基或羧基的生物同位素，R3代表氢原子，C1-4烷基或C7-12芳基烷基，m代表0或1。
• PAI-1 INHIBITOR
  申请人：Yamaguchi Youichi

  公开号：US20090312315A1

  公开（公告）日：2009-12-17

  The compound represented by the following formula (I) and the like have PAI-1 inhibition activity; wherein: R 1 represents a C 6-10 aryl group which may be substituted or the like; T represents a single bond or the like; m represents 0 or 1; when m is 0, G represents —N—C(═O)—CO 2 H or the like; when m is 1, G represents an oxygen atom or the like; R 2 represents a C 6-10 aryl group which may be substituted or the like; E represents the following formula (II) wherein one of R 31 , R 32 , R 33 and R 34 represents the formula R 1 -T-, each of the other three independently represents a hydrogen atom or the like, and R 35 represents the formula —X—Y′, a hydrogen atom or the like; X represents —CH 2 — or the like; Y′ represents a carboxy group or the like; M represents a single bond or the like.

  以下公式（I）表示的化合物及类似化合物具有PAI-1抑制活性；其中：R1代表可能被取代的C6-10芳基或类似基团；T代表单键或类似键；m代表0或1；当m为0时，G代表—N—C(═O)—CO2H或类似基团；当m为1时，G代表氧原子或类似基团；R2代表可能被取代的C6-10芳基或类似基团；E代表以下公式（II），其中R31、R32、R33和R34中的一个代表公式R1-T-，其余三个分别独立地代表氢原子或类似基团，R35代表公式—X—Y′，氢原子或类似基团；X代表—CH2—或类似基团；Y′代表羧基或类似基团；M代表单键或类似键。
• SHORT SYNTHESIS OF TOLTERODINE, INTERMEDIATES AND METABOLITES
  申请人：Sterk Damjan

  公开号：US20130197082A1

  公开（公告）日：2013-08-01

  A process is described for the preparation of intermediates which can be used for preparation of agents for urinary incontinence therapy, specifically to 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol and its prodrugs.

  描述了一种制备中间体的过程，该中间体可用于制备尿失禁治疗剂，特别是用于制备2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟甲基)苯酚及其前药。
• Novel derivatives of 3,3-diphenylpropylamines
  申请人：Schwarz Pharma AG

  公开号：US20040186061A1

  公开（公告）日：2004-09-23

  The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

  本发明涉及3,3-二苯基丙胺衍生物的新型衍生物，其制备方法，含有新型化合物的药物组合物以及用于制备药物的化合物的用途。更具体地说，本发明涉及优于现有药物如奥克西布丁和托尔特罗定的抗胆碱药物的新型前药，其药代动力学性质更优，其制备方法，含有它们的药物组合物，一种使用所述化合物和组合物治疗尿失禁，胃肠道过度活跃（肠易激综合征）和其他平滑肌收缩症状的方法。